Growing Incidence of Hormone-Sensitive Cancers
Across the region, hormone-responsive cancers are rising due to rapid population aging, urbanization, and expanding cancer awareness. Breast cancer is now the leading cancer among women in countries such as China, Japan, South Korea, and Australia, with a growing proportion classified as estrogen or progesterone receptor–positive. Prostate cancer incidence is climbing, particularly in Japan, South Korea, and urban China, reflecting demographic shifts and greater adoption of PSA-based screening. While incidence rates vary widely across the region, longer survival and increased early detection are driving a sustained demand for hormone therapy.
Rising obesity, sedentary behavior, and adoption of Western diets in urban centers of China, South Korea, and Singapore contribute to higher breast cancer risk, while delayed childbirth and reduced breastfeeding rates increase hormone receptor–positive cases. In Japan and Australia, national cancer registries indicate that over 70% of newly diagnosed breast cancers are hormone receptor–positive, highlighting the expanding patient population eligible for endocrine therapy. Similarly, improved prostate cancer detection in China and South Korea is increasing the number of patients starting androgen-deprivation therapy.
High-income countries such as Japan, South Korea, and Australia provide broad access to oral and injectable endocrine agents through public and private systems. Middle-income countries such as China, India, and Indonesia face distribution challenges in rural areas. National cancer control plans are including hormone therapy in essential medicines lists, promoting standardized treatment protocols. As awareness, early detection, and survivorship improve, hormone therapy is becoming a foundational component of cancer management across Asia Pacific.
Growing Adoption of Combination Therapies
In hormone receptor–positive breast cancer, combinations of aromatase inhibitors or fulvestrant with CDK4/6 inhibitors or PI3K/mTOR pathway inhibitors are used in Japan, South Korea, and Australia, supported by reimbursement mechanisms and guideline adoption. These combinations allow earlier initiation in advanced disease, extend therapy duration, and increase per-patient drug consumption.
In prostate cancer, androgen-deprivation therapy combined with next-generation androgen receptor inhibitors or chemotherapy is becoming standard practice in Japan and South Korea for metastatic hormone-sensitive disease. Urban centers in China and Australia are adopting similar strategies, although access is uneven in rural or resource-constrained settings. Sequential hormone therapies play a role in countries with limited access to newer agents, reflecting a gradual shift toward more comprehensive, multi-drug approaches.
Policy frameworks, clinical training, and real-world evidence initiatives are accelerating combination therapy adoption. Japan and South Korea have well-established health technology assessment processes supporting coverage for novel combinations. Multinational collaborations are expanding clinician expertise and guideline implementation in emerging markets. Pharmaceutical access programs and digital registries enable monitoring of outcomes and adherence to combination protocols. As healthcare infrastructure matures and precision oncology advances, combination hormone therapy is poised to be a major growth driver for the Asia Pacific cancer hormone therapy market.
